LifeTec 生命科技集團有限公司 LifeTec Group Limited

Press Release

LIFETEC GROUP ANNOUNCED

"WEI JIA" WAS FURTHER RECOGNIZED BY THE PRC GOVERNMENT

(6 May 2004, Hong Kong) - **LifeTec Group Limited** ("LifeTec" or "the Group") (HKEX code: 1180) announced that the trial standard of Wei Jia, a Category One Western New Drug, was upgraded by China's State Food and Drug Administration ("SFDA"). **"Wei Jia" was accredited a new and formal standard which indicates "Wei Jia" was further recognized by SFDA.**

"Wei Jia"(Hepatocyte Growth Factor "pHGF"**)** is a Category One Western New Drug developed exclusively by LifeTec. "Wei Jia" commands a premium status as so far only 19 Category One drugs have been approved in history of China. LifeTec is a prescription product designated for hospital use in the treatment of severe hepatitis B. Formulated as an intravenous injection, Wei Jia is a highly purified Hepatocyte Growth Factor, which promotes repair and growth in liver cells. Clinical results testify to the overall efficacy and safety of Wei Jia and the absence of any significant side effects when it is used to treat severe hepatitis B.

The upgrading of standard by SFDA indicating that "Wei Jia" was further admitted by the government. According to the new standard, the preservation period of Wei Jia was extended from one year to two years, indicating that the new standard was even more advanced than the one previously set by SFDA.

The new standard will be effective as from 17 June 2004.

About LifeTec

LifeTec is a Hong Kong listed company (stock code 1180), which develops, sells and distributes biopharmaceutical products based on original technology. LifeTec owns the intellectual property, production know-how and worldwide exclusive distributorship of the new generation hepatitis drug Wei Jia, a Category I drug approved by China's State Food and Drug Administration.

With 120 million hepatitis B carriers, China is the world's largest market for hepatitis drugs. With Lifetec's outstanding sales and marketing capability, the number of hospitals adopting Wei Jia for hepatitis treatment soared from 500 in 2002 to about 700 as at the end of 2003. LifeTec is also licensed to sell and distribute third parties' biopharmaceutical products through its nationwide distribution network.

For new product pipeline, LifeTec is working on recombinant human augmenter for liver regeneration ("rhALR"), a revolutionary gene therapy for various kinds of liver diseases, and Fibroscutum, a novel anti-fibrosis and anti-cancer compound. The two new products are the Group's strategic move to develop genetic drugs.

- End -

For Enquiries
LifeTec Group Limited
Ms. Michelle Chan
michellechan@hk1180.com
Tel: (852) 2916 0813 Fax: (852) 2620 6000
Website: www.hk1180.com